Vonoprazan (BioDeep_00000858748)
代谢物信息卡片
Vonoprazan
化学式: C17H16FN3O2S (345.0947)
中文名称: 沃诺拉赞
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3
InChI: InChI=1S/C17H16FN3O2S/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14/h2-9,11-12,19H,10H2,1H3
描述信息
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:136048
- KEGGdrug: D11784
- PubChem: 15981397
- DrugBank: DB11739
- ChEMBL: CHEMBL2079130
- CAS: 881681-00-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Ying-Ying Han, Lin Zhou, Yun-Lian Hu, Xiang-Wu Ding, Hui Long, Fei Liu, Ming Xu, Zhen-Yu Zhang, Shuang-Ling Li, Qiu-Yan Wang, Cheng-Xia Su, Yan Chen, Jie Chen, Ya Lin, Pei-Yuan Li. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Journal of gastroenterology.
2023 Oct; ?(?):. doi:
10.1007/s00535-023-02042-2. [PMID: 37777987] - Jie He, Yuanyuan Gao, Ge Bai, Jie Wang, Yongshun Sun. Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis.
Journal of comparative effectiveness research.
2023 08; 12(8):e220165. doi:
10.57264/cer-2022-0165. [PMID: 37470274] - Shasha Chen, Weina Shen, Yuhuan Liu, Qiang Dong, Yongquan Shi. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chinese medical journal.
2023 Jul; 136(14):1690-1698. doi:
10.1097/cm9.0000000000002696. [PMID: 37469024] - Tiaotiao Miao, Yao Zhang, Lin Bai, Xiangqian Yang, Xinli Wen. Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis.
Revista espanola de enfermedades digestivas.
2023 04; 115(4):168-174. doi:
10.17235/reed.2022.8863/2022. [PMID: 35899702] - Chen Yang, Sai Li, Taoyang Huang, Hongju Lin, Zhihui Jiang, Yongyang He, Junjie Yuan, Huijie An. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Journal of clinical pharmacy and therapeutics.
2022 Jul; 47(7):897-904. doi:
10.1111/jcpt.13637. [PMID: 35247003] - Tomohiro Higuchi, Mihoko Yamade, Satoru Takahashi, Satoshi Tamura, Shinya Tani, Takuma Kagami, Takahiro Uotani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Takahisa Furuta. Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.
European journal of clinical pharmacology.
2022 Jun; 78(6):955-963. doi:
10.1007/s00228-022-03313-2. [PMID: 35445847] - Darcy J Mulford, Eckhard Leifke, Mark Hibberd, Colin W Howden. The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Clinical pharmacology in drug development.
2022 02; 11(2):278-284. doi:
10.1002/cpdd.1009. [PMID: 34431240] - Ki Young Huh, Hyewon Chung, Yu Kyong Kim, SeungHwan Lee, Siddharth Bhatia, Yohei Takanami, Ryou Nakaya, Kyung-Sang Yu. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
British journal of clinical pharmacology.
2022 01; 88(1):138-144. doi:
10.1111/bcp.14934. [PMID: 34080718] - Yun Hong, Da-Peng Dai, Jian-Ping Cai, Shuang-Hu Wang, Yi-Ran Wang, Fang-Ling Zhao, Shan Zhou, Quan Zhou, Pei-Wu Geng, Yun-Fang Zhou, Xue Xu, Ji-Hua Shi, Qing-Feng Luo. Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo.
Drug design, development and therapy.
2022; 16(?):1779-1789. doi:
10.2147/dddt.s365610. [PMID: 35707687] - Shogo Watari, Motoo Araki, Jun Matsumoto, Kasumi Yoshinaga, Takanori Sekito, Yuki Maruyama, Yosuke Mitsui, Takuya Sadahira, Risa Kubota, Shingo Nishimura, Koichiro Wada, Yasuyuki Kobayashi, Hidemi Takeuchi, Katsuyuki Tanabe, Masashi Kitagawa, Hiroshi Morinaga, Shinji Kitamura, Hitoshi Sugiyama, Noritaka Ariyoshi, Jun Wada, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu. Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms.
Drug metabolism and pharmacokinetics.
2021 Oct; 40(?):100407. doi:
10.1016/j.dmpk.2021.100407. [PMID: 34352707] - Kazuhiro Ota, Toshihisa Takeuchi, Yuichi Kojima, Shimpei Kawaguchi, Taro Iwatsubo, Akitoshi Hakoda, Shinya Nishida, Shun Sasaki, Satoshi Kikutani, Hideki Tawa, Hideaki Kanaoka, Naofumi Osaka, Michiaki Takii, Koji Nakada, Kazuhide Higuchi. Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial.
Journal of gastroenterology.
2021 08; 56(8):722-731. doi:
10.1007/s00535-021-01801-3. [PMID: 34155580] - Takahiro Suzuki, Tomohiro Higuchi, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Shinya Tani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia.
European journal of clinical pharmacology.
2021 Jul; 77(7):971-978. doi:
10.1007/s00228-021-03162-5. [PMID: 34059932] - Wei-Min Kong, Bin-Bin Sun, Zhong-Jian Wang, Xiao-Ke Zheng, Kai-Jing Zhao, Yang Chen, Jia-Xin Zhang, Pei-Hua Liu, Liang Zhu, Ru-Jun Xu, Ping Li, Li Liu, Xiao-Dong Liu. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans.
Acta pharmacologica Sinica.
2020 Jun; 41(6):852-865. doi:
10.1038/s41401-019-0353-2. [PMID: 31969689] - Sherif S Ebada, Nariman A Al-Jawabri, Fadia S Youssef, Amgad Albohy, Sa'ed M Aldalaien, Ahmad M Disi, Peter Proksch. In vivo antiulcer activity, phytochemical exploration, and molecular modelling of the polyphenolic-rich fraction of Crepis sancta extract.
Inflammopharmacology.
2020 Feb; 28(1):321-331. doi:
10.1007/s10787-019-00637-x. [PMID: 31482260] - Takanori Mei, Hiroshi Noguchi, Kimitaka Suetsugu, Yu Hisadome, Keizo Kaku, Yasuhiro Okabe, Satohiro Masuda, Masafumi Nakamura. Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients.
Biological & pharmaceutical bulletin.
2020; 43(10):1600-1603. doi:
10.1248/bpb.b20-00361. [PMID: 32999170] - Libin Wang, Shouchang Gai, Xiaorui Zhang, Xiaohui Xu, Nan Gou, Xingchen Wang, Nan Zhou, Tian Feng. Simultaneous determination of Rivaroxaban and TAK-438 in rat plasma by LC-MS/MS: application to pharmacokinetic interaction study.
Bioanalysis.
2020 Jan; 12(1):11-22. doi:
10.4155/bio-2019-0130. [PMID: 31849262] - Jiquan Shen, Bo Wang, Shuanghu Wang, Feifei Chen, Deru Meng, Hui Jiang, Yunfang Zhou, Peiwu Geng, Quan Zhou, Bin Liu. Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats.
Drug design, development and therapy.
2020; 14(?):2199-2206. doi:
10.2147/dddt.s255427. [PMID: 32581516] - Junichi Akiyama, Hiroko Hosaka, Shiko Kuribayashi, Shiori Moriyasu, Yuya Hisada, Hidetaka Okubo, Kazuhiro Watanabe, Koh Imbe, Naoyoshi Nagata, Yasushi Kojima, Chizu Yokoi, Naomi Uemura, Yasuyuki Shimoyama, Osamu Kawamura, Masanobu Yamada, Motoyasu Kusano. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Digestion.
2020; 101(2):174-183. doi:
10.1159/000497775. [PMID: 30897577] - Feifei Chen, Hui Jiang, Jia Xu, Shuanghu Wang, Deru Meng, Peiwu Geng, Dapeng Dai, Quan Zhou, Yunfang Zhou. In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine.
Drug design, development and therapy.
2020; 14(?):4815-4824. doi:
10.2147/dddt.s276704. [PMID: 33204067] - Tsutomu Nishida, Yuri Tsujii, Akino Okamoto, Ryo Tomita, Yu Higaki, Naoto Osugi, Aya Sugimoto, Kei Takahashi, Kaori Mukai, Dai Nakamatsu, Tokuhiro Matsubara, Shiro Hayashi, Masashi Yamamoto, Sachiko Nakajima, Koji Fukui, Masami Inada. A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study.
Digestion.
2020; 101(5):608-614. doi:
10.1159/000501608. [PMID: 31288235] - Kiyoshi Ashida, Youichirou Honda, Katsuyuki Sanada, Yukiko Takemura, Shigeru Sakamoto. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance.
Expert opinion on drug safety.
2019 Dec; 18(12):1255-1261. doi:
10.1080/14740338.2019.1676722. [PMID: 31646920] - Mitsuhiro Nishihara. Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes.
European journal of drug metabolism and pharmacokinetics.
2019 Oct; 44(5):713-717. doi:
10.1007/s13318-019-00554-y. [PMID: 30993551] - Ryohkan Funakoshi, Yukana Tomoda, Toshiyuki Kudo, Kenichi Furihata, Hiroyuki Kusuhara, Kiyomi Ito. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
British journal of clinical pharmacology.
2019 07; 85(7):1454-1463. doi:
10.1111/bcp.13914. [PMID: 30845361] - Mitsuhiro Nishihara, Hitomi Yamasaki, Richard Czerniak, Helen Jenkins. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.
European journal of drug metabolism and pharmacokinetics.
2019 Apr; 44(2):217-227. doi:
10.1007/s13318-018-0521-7. [PMID: 30361928] - Naoto Iwai, Takashi Okuda, Kohei Oka, Tasuku Hara, Yutaka Inada, Toshifumi Tsuji, Toshiyuki Komaki, Ken Inoue, Osamu Dohi, Hideyuki Konishi, Yuji Naito, Yoshito Itoh, Keizo Kagawa. Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study.
PloS one.
2019; 14(8):e0221349. doi:
10.1371/journal.pone.0221349. [PMID: 31419266] - Tianyi Li, Hongqun Qiao, Peng Yue, Ming Cai, Xuejun He. Embryo-fetal toxicity assessment of vonoprazan in rats and rabbits.
Journal of applied toxicology : JAT.
2018 07; 38(7):987-995. doi:
10.1002/jat.3607. [PMID: 29659034] - Chika Kusano, Takuji Gotoda, Sho Suzuki, Hisatomo Ikehara, Mitsuhiko Moriyama. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Journal of gastroenterology.
2018 Jun; 53(6):718-724. doi:
10.1007/s00535-017-1406-2. [PMID: 29110085] - Takashi Kawai, Kazunori Oda, Nobuo Funao, Akira Nishimura, Yasushi Matsumoto, Yuji Mizokami, Kiyoshi Ashida, Kentaro Sugano. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Gut.
2018 06; 67(6):1033-1041. doi:
10.1136/gutjnl-2017-314852. [PMID: 29196436] - Kiyoshi Ashida, Katsuhiko Iwakiri, Naoki Hiramatsu, Yuuichi Sakurai, Tetsuharu Hori, Kentarou Kudou, Akira Nishimura, Eiji Umegaki. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
World journal of gastroenterology.
2018 Apr; 24(14):1550-1561. doi:
10.3748/wjg.v24.i14.1550. [PMID: 29662293] - Takahiro Suzuki, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin.
European journal of clinical pharmacology.
2018 Jan; 74(1):45-52. doi:
10.1007/s00228-017-2324-1. [PMID: 28986609] - Yuan Qiao, Jun Zhao, Xuanfeng Yue, Yang Zhang, Ruitao Zhang, Yuan Xu, Xiuling Tang, Xueying Liu, Qingwei Wang. Study on pharmacokinetics and bioequivalence of Vonoprazan pyroglutamate in rats by liquid chromatography with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2017 Aug; 1059(?):56-65. doi:
10.1016/j.jchromb.2017.05.013. [PMID: 28578848] - B Astruc, H Jenkins, R Jenkins. Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects.
Clinical and translational science.
2017 05; 10(3):208-216. doi:
10.1111/cts.12452. [PMID: 28198590] - Akifumi Kogame, Toshiyuki Takeuchi, Masami Nonaka, Hitomi Yamasaki, Naohiro Kawaguchi, Ai Bernards, Yoshihiko Tagawa, Akio Morohashi, Takahiro Kondo, Toshiya Moriwaki, Satoru Asahi. Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.
Xenobiotica; the fate of foreign compounds in biological systems.
2017 Mar; 47(3):255-266. doi:
10.1080/00498254.2016.1182667. [PMID: 27225050] - Helen Jenkins, Richard Jenkins, Alain Patat. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.
Clinical drug investigation.
2017 Mar; 37(3):311-316. doi:
10.1007/s40261-016-0488-6. [PMID: 27928738] - Yuuichi Sakurai, Madoka Shiino, Sayako Horii, Hiroyuki Okamoto, Koki Nakamura, Akira Nishimura, Yukikuni Sakata. Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men.
Clinical drug investigation.
2017 Jan; 37(1):39-49. doi:
10.1007/s40261-016-0455-2. [PMID: 27581248] - Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Akira Nishimura, Koki Nakamura, Setsuo Hasegawa. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Advances in therapy.
2016 09; 33(9):1519-35. doi:
10.1007/s12325-016-0374-x. [PMID: 27432383] - Kazuyoshi Otake, Yuuichi Sakurai, Haruyuki Nishida, Hideo Fukui, Yoshihiko Tagawa, Hitomi Yamasaki, Masatoshi Karashima, Keiichi Otsuka, Nobuhiro Inatomi. Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).
Advances in therapy.
2016 07; 33(7):1140-57. doi:
10.1007/s12325-016-0345-2. [PMID: 27287852] - Jun Matsukawa, Akifumi Kogame, Yoshihiko Tagawa, Nobuhiro Inatomi. Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.
Digestive diseases and sciences.
2016 07; 61(7):1888-94. doi:
10.1007/s10620-016-4100-y. [PMID: 26961787] - Hirotoshi Echizen. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Clinical pharmacokinetics.
2016 Apr; 55(4):409-18. doi:
10.1007/s40262-015-0326-7. [PMID: 26369775] - Tomoki Yoneyama, Koichiro Teshima, Fumihiro Jinno, Takahiro Kondo, Satoru Asahi. A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Mar; 1015-1016(?):42-49. doi:
10.1016/j.jchromb.2016.01.051. [PMID: 26896571] - D R Scott, K B Munson, E A Marcus, N W G Lambrecht, G Sachs. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.
Alimentary pharmacology & therapeutics.
2015 Dec; 42(11-12):1315-26. doi:
10.1111/apt.13414. [PMID: 26423447] - H Jenkins, Y Sakurai, A Nishimura, H Okamoto, M Hibberd, R Jenkins, T Yoneyama, K Ashida, Y Ogama, S Warrington. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Alimentary pharmacology & therapeutics.
2015 Apr; 41(7):636-48. doi:
10.1111/apt.13121. [PMID: 25707624] - Yasunobu Hori, Jun Matsukawa, Toshiyuki Takeuchi, Haruyuki Nishida, Masahiro Kajino, Nobuhiro Inatomi. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
The Journal of pharmacology and experimental therapeutics.
2011 Jun; 337(3):797-804. doi:
10.1124/jpet.111.179556. [PMID: 21411494]
